G
Gate2Brain
Spain · Biotech
Gate2Brain develops peptide shuttles that help therapeutic compounds cross the blood-brain barrier.
Product
The Barcelona company develops treatments for central nervous system diseases using its MiniAp4 delivery technology. Its lead programme, G2B-002, couples the shuttle with an anticancer payload for aggressive brain tumours.
Gate2Brain is advancing the programme from preclinical research toward human studies with manufacturing and regulatory partners.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Strategic equity partnership; cash component | €500K | Shilpa Biocare — Participant |